This product is available in the following Dual antiplatelet therapy with aspirin and a platelet P2Y 12 receptor antagonist (P2Y 12 inhibitor) is the treatment of choice for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) and for those undergoing percutaneous coronary intervention (PCI)
3 This active form is a platelet inhibitor that irreversibly binds to P2Y 12 ADP receptors on platelets
Clopidogrel: a review of its mechanism of action
warfarin) and
1
Objectives Evidence of the optimal antiplatelet therapy for elderly patients
This medicine is available only with your doctor's prescription
In patients with chronic symptomatic PAD, aspirin is commonly prescribed as a long-term single antiplatelet therapy although clopidogrel may also be prescribed [107,108]
These effects last for the life of the anucleate platelet, approximately 7 to 10 days
Recommendation: Alternative antiplatelet therapy (if no contraindication); e
prasugrel, ticagrelor) if no contraindication
ticlopidine
Acute coronary syndrome (ACS) is a term used to encompass unstable angina (UA) and myocardial infarction (MI) with or without electrocardiographic (ECG) evidence of ST-segment elevation
[1] These agents are used to decrease major adverse events due to acute coronary syndromes, peripheral vascular disease, and stroke
An oral medication used for the reduction of thrombotic stroke risk, transient ischemic attack (TIA) prophylaxis, and post-myocardial infarcion (MI) prevention of thrombosis
Cilostazol is also indicated for secondary prevention in patients with a history of transient ischemic attacks or non-cardioembolic ischaemic stroke
Antiplatelet agents that are currently approved by the Food and Drug Administration for secondary stroke prevention include aspirin, clopidogrel, and dipyridamole
Aspirin (ASA) blocks cyclooxygenase, an enzyme produced by platelets, and is a well-established treatment for acute coronary syndromes reducing further vascular events
1 %, and among patients on dual antiplatelet treatment with aspirin and clopidogrel, the risk was 6
Because the mechanism of clopidogrel’s antiplatelet effect is blockade of the P2Y 12 ADP receptor , clopidogrel’s effect on platelet function can be measured by stimulation of platelets with ADP and the use of 1 of a number of readouts (eg, phosphorylation of vasodilator-stimulated phosphoprotein measured